Surfing the MASH Tsunami

Send us Fan Mail The conversation looks at how the NAIL-NIT program design improves on the quality of insight provided by the NAS score, both in terms of drug development and treatment of individual patients. Also, note that during this conversation, Mazen Noureddin thanks a relatively large group of individuals and companies supporting this project.  The first section focuses mostly on what we ca...

Send us Fan Mail NAIL-NIT is both a response to the challenges of histopathology and an effort to create a different vision of testing liver patients. This episode starts with Stephen Harrison describing the events that came to demonstrate how challenging current histopathology approaches: a series of drug development failures that reflect shortcomings in methodology rather than in the development...

Send us Fan Mail NAIL-NIT is a new NAFLD consortium dedicated to exploring the direct relationship between non-invasive testing (NITs) and outcomes in Fatty Liver disease. In this opening conversation, study co-directors Stephen Harrison and Mazen Noureddin are joined by Steering Committee members Amy Articolo, Medical Director for NASH at Novo Nordisk and Senthil Sundaram, CEO of Terns Pharmaceut...

Send us Fan Mail Co-director Mazen Noureddin and Steering Committee members Amy Articolo of Novo Nordisk and Senthil Sundaram of Terns Pharmaceuticals join the Surfers (Stephen Harrison is also a co-director) to discuss the NAIL-NIT Consortium, an ambitious effort to link non-invasive testing (and specific tests) directly to outcomes.  NAIL-NIT's activities include a prospective six-year stud...

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen first and how often to screen after that. This wrap-up conversation wrestles with the question who to screen, when to start and how to reckon with the dual challenge that the early effects of Fatty Liver...

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen first and how often to screen after that. This conversation asks what we can learn from trial results and, separately, the clinical experiences of practitioners and patients about the value of early testi...

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen first and how often to screen after that. This conversation focuses on the paper Screening for undiagnosed NAFLD and NASH: A population-based risk factor assessment using Vibration-Controlled Transient El...

Send us Fan Mail Episode 10 dives into recent NAFLD and NASH Prevalence studies in the US, UK and Germany and explores what this can tell us about who to screen for NAFLD and NASH, when to screen first and how often to screen after that. This conversation focuses on the paper Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population-Based Study in Germany, which was published last Sat...

Send us Fan Mail This episode looks at four different sources of data estimating NASH and NAFLD prevalence in population subgroups the US, UK and Germany. All four suggest that the share of people living with NAFLD might be as high as three in eight. This is far too high a screening burden for the hepatology community to manage on its own. However, it should have broader implications for overall t...

Send us Fan Mail This conversation explores the need for and value of patient education in the NASH Patient Care process. It starts with almost a tangential request that some of the money budgeted for expensive systemic HCC therapies in the UK be rededicated to patient education earlier in the treatment process. It starts with almost a tangential request that some of the money budgeted for expensi...

Send us Fan Mail This conversation explores the different challenges that liver nurses and advanced practitioners face when providing NASH patient education. It starts with Stephen Harrison noting that this weeks' reported results from Madrigal's MAESTRO-NAFLD Phase 3 trial promises a day when we can reduce HCC and cirrhosis if we can counsel patients early enough in the process.  From t...

Send us Fan Mail This conversation explores the different challenges that liver nurses and advanced practitioners face when providing NASH patient support. It focuses on issues including health discrimination, the general challenges in deploying nursing care early in the disease progression and the mismatch of needs and resources. In the end, we learn about nurses who make their own recordings and...

Send us Fan Mail Episode 9 asks the question, "Are We Taking Full Advantage of the Skills and Knowledge that Liver Nurses and Advanced Nurse Practitioners Bring To NASH Patient Care and Education?"  In this conversation, we meet the four key nursing opinion leaders who have joined Louise Campbell and Stephen Harrison for the full episode. You will get to meet Kathryn Jack, Michelle Clayt...

Send us Fan Mail Louise Campbell convenes  liver nursing and nurse educator experts Kathryn Jack, Michele Clayton, Pam O'Donoghue and Patrizia Kunzler to consider where liver nurses and advanced nursing practitioners should fit into treatment and communication paradigms and what support they will need. Stephen Harrison joined to offer a different viewpoint. Timestamps: 2:42 – Roger introduces...

Send us Fan Mail The Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this conversation, Stephen Harrison, Louise Campbell and Roger Green join Professors...

Send us Fan Mail The Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this conversation, Stephen Harrison, Louise Campbell and Roger Green join Professors...

Send us Fan Mail The Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this conversation, Stephen Harrison, Louise Campbell and Roger Green join Professors...

Send us Fan Mail The Innovations in NAFLD Care 2022 Series includes a recent webinar and a hybrid meeting planned for Barcelona in May. This new event is a key new element in the effort to drive more holistic multi-specialty approaches toward diagnosis, treatment and management of patients with NAFLD and NASH. In this 10-minute conversation, Professors Schattenberg and Lazarus outline the social a...

Send us Fan Mail Program co-chairs Jeff Lazarus and Jörn Schattenberg join the Surfers to discuss their "Innovations in NAFLD Care 2022" series and how it promotes the broader NAFLD Public Health Agenda. This far-ranging discussion focuses on the Innovations in NAFLD Care 2022 webinar and event series with the goal of understanding what makes this series special and why it is so importan...

Send us Fan Mail Roger Green assemblies audio clips from Surfing the NASH Tsunami's coverage of NASH-TAG 2022 to reveal an evolving view of the role combination therapies will play in treatment and management of NASH patients. Discussion about "combination therapies" typically focuses on the idea of multiple agents prescribed concurrently to address a medical condition when monother...

Send us Fan Mail Global Liver Institute Founder and CEO Donna Cryer and Key Opinion Leader Professor Scott Friedman joined Roger Green at NASH-TAG 2022 for a far-reaching conversation on drug development and scientific advances in Fatty Liver disease. This episode includes the entire discussion, plus a shorter one with Roger and  SurfingNASH co-host Louise Campbell on some of the lessons emerging...

Send us Fan Mail Last weekend's NASH-TAG 2022 was the best attended event in the conference's six-year history, and probably the one that will have the greatest long-term impact on diagnosis, treatment and monitoring of Fatty Liver patients. In this wrap-up conversation, our seven-person panel (including two Pharma execs and one diagnostics entrepreneur) discusses strategies for improvin...

Send us Fan Mail Last weekend's NASH-TAG 2022 was the best attended event in the conference's six-year history, and probably the one that will have the greatest long-term impact on diagnosis, treatment and monitoring of Fatty Liver patients. In this wrap-up conversation, our seven-person panel (including two Pharma execs and one diagnostics entrepreneur) considers how two key stakeholder...

Send us Fan Mail Last weekend's NASH-TAG 2022 was the best attended event in the conference's six-year history, and probably the one that will have the greatest long-term impact on diagnosis, treatment and monitoring of Fatty Liver patients. In this wrap-up conversation, our seven-person panel (including two Pharma execs and one diagnostics entrepreneur) discusses reactions to the closin...

Send us Fan Mail Last weekend's NASH-TAG 2022 was the best attended event in the conference's six-year history, and probably the one that will have the greatest long-term impact on diagnosis, treatment and monitoring of Fatty Liver patients. In this wrap-up conversation, our seven-person panel (including two Pharma execs and one diagnostics entrepreneur) identifies what each participant...